PITTSBURGH, PA, USA I December 13, 2016 I Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the initiation of U.S. clinical testing of CT1812, its proprietary first-in-class, orally available small molecule therapeutic being developed for the treatment of Alzheimer’s disease. The first US patient was dosed under Cognition’s recently submitted US IND in a drug-drug interaction study, which will support Cognition’s ongoing clinical testing of CT1812 in patients with Alzheimer’s disease in Australia.
“The initiation of US clinical testing of CT 1812 represents an important milestone for Cognition as we expand our understanding of the molecule’s potential for the treatment of individuals with Alzheimer’s disease,” said Kenneth I. Moch, President & CEO of Cognition. “CT1812’s unique mechanism of action, coupled with its high bioavailability and significant penetration across the blood brain barrier, has the potential to differentiate the molecule from all other compounds currently under development in this important therapeutic area.”
About CT1812
CT1812 is a proprietary first-in-class, orally available small molecule that displaces bound beta amyloid oligomers and inhibits binding of Aβ oligomers to the receptor complex. The molecule was designed by Cognition’s scientific team, led by Susan Catalano, Ph.D., to target and displace the toxic beta amyloid oligomers that cause Alzheimer’s disease. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss.
In Cognition’s ongoing Study COG0102, patients with mild to moderate Alzheimer’s disease are being randomized to one of two doses of CT1812 (280mg patients or 560mg) or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Cognition has previously conducted single and multiple ascending dose studies in 94 healthy volunteers, 74 of whom received CT1812. Study COG0102 is supported in part under Award Number RF1AG054176 from the National Institute on Aging of the National Institutes of Health.
About Cognition Therapeutics, Inc.
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Additional information about Cognition may be found online at http://www.cogrx.com.
SOURCE: Cognition Therapeutics
Post Views: 29
PITTSBURGH, PA, USA I December 13, 2016 I Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the initiation of U.S. clinical testing of CT1812, its proprietary first-in-class, orally available small molecule therapeutic being developed for the treatment of Alzheimer’s disease. The first US patient was dosed under Cognition’s recently submitted US IND in a drug-drug interaction study, which will support Cognition’s ongoing clinical testing of CT1812 in patients with Alzheimer’s disease in Australia.
“The initiation of US clinical testing of CT 1812 represents an important milestone for Cognition as we expand our understanding of the molecule’s potential for the treatment of individuals with Alzheimer’s disease,” said Kenneth I. Moch, President & CEO of Cognition. “CT1812’s unique mechanism of action, coupled with its high bioavailability and significant penetration across the blood brain barrier, has the potential to differentiate the molecule from all other compounds currently under development in this important therapeutic area.”
About CT1812
CT1812 is a proprietary first-in-class, orally available small molecule that displaces bound beta amyloid oligomers and inhibits binding of Aβ oligomers to the receptor complex. The molecule was designed by Cognition’s scientific team, led by Susan Catalano, Ph.D., to target and displace the toxic beta amyloid oligomers that cause Alzheimer’s disease. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss.
In Cognition’s ongoing Study COG0102, patients with mild to moderate Alzheimer’s disease are being randomized to one of two doses of CT1812 (280mg patients or 560mg) or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Cognition has previously conducted single and multiple ascending dose studies in 94 healthy volunteers, 74 of whom received CT1812. Study COG0102 is supported in part under Award Number RF1AG054176 from the National Institute on Aging of the National Institutes of Health.
About Cognition Therapeutics, Inc.
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Additional information about Cognition may be found online at http://www.cogrx.com.
SOURCE: Cognition Therapeutics
Post Views: 29
